3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, MY; Li, J; Wang, JJ | 1 |
| Chen, S; Cohen-Sola, KA; Goydos, JS; Jeong, BS; Koo, J; Li, J; Lin, Y; Mehnert, JM; Shin, SS; Wen, Y | 1 |
1 review(s) available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and sirolimus
| Article | Year |
|---|---|
[Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Topics: Amphotericin B; Animals; Antineoplastic Agents; Echinomycin; Humans; Hypoxia-Inducible Factor 1; Indazoles; Sirolimus; Topotecan; Transcription, Genetic | 2008 |
1 other study(ies) available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and sirolimus
| Article | Year |
|---|---|
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Inhibitor of Apoptosis Proteins; Interleukin-8; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sirolimus; Skin Neoplasms; Survivin; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |